PE HUB Healthcare Wire Highlights, 8.1.19

How Bain leverages collaboration with tech, life sciences teams

Hello, everybody!

It’s August, the sun is out, and there remains no shortage of healthcare news or drama. Time sure does fly when investors are pulling all-nighters and billion dollar deals are getting done on a weekly basis.

But first, let’s talk movers and shakers.

Well-known investor Jim Momtazee is leaving KKR after more than 20 years at the firm, including about a decade leading healthcare efforts.

Ali Satvat and Max Lin, already senior leaders of the healthcare team, will take the reins to co-head KKR’s healthcare efforts in the Americas. Satvat has already been leading the charge at the firm’s first ever Healthcare Strategic Growth Fund, a $1.45 billion pool of capital.

Read my story with my colleague Chris Witkowsky here.

In other notable moves this year, General Atlantic poached Justin Sunshine from Blackstone to help pursue growth investments in healthcare. Read more here.

It remains unclear why Momtazee departed and what’s next on the agenda. Could there be another first-time manager on the horizon? Hear word of any other big names on the move? Reach me at

Spotlight: Bain Capital

Bain Capital has been involved in billions of dollars of healthcare activity as both a buyer and seller this summer.

Though a deal has yet to be formally announced, last week I learned that Bain struck an agreement to invest in Parthenon Capital’s merger of a pair of healthcare fintech companies: Zelis Healthcare and RedCard. The deal commanded a $5.7 billion valuation, I learned.